Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)
Conditions
Interventions
CVT-301 Low Dose
CVT-301 High Dose
+1 more
Locations
74
United States
Acorda Site #5020
Scottsdale, Arizona, United States
Acorda Site #5042
Fresno, California, United States
Acorda Site #5064
Fullerton, California, United States
Acorda Site #5035
Loma Linda, California, United States
Acorda Site #5027
Long Beach, California, United States
Acorda Site #5037
Los Angeles, California, United States
Start Date
November 1, 2014
Primary Completion Date
December 1, 2016
Completion Date
December 1, 2016
Last Updated
May 28, 2019
NCT01221948
NCT05094011
NCT02610231
NCT01668407
NCT03665493
NCT05575479
Lead Sponsor
Acorda Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions